We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rheumatoid Arthritis Test Predicts Patient Response to Drugs

By LabMedica International staff writers
Posted on 25 Nov 2015
A diagnostic for measuring the severity of rheumatoid arthritis can help guide patient selection for biologic or non-biologic drugs by predicting their response to the various therapies and treatment strategies.

The multi-biomarker blood test for rheumatoid arthritis disease (RA) activity integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score, on a scale of 1 to 100, to help physicians make more informed treatment decisions.

A recent study from scientists at Helsingborg Hospital (Sweden) evaluated whether the Vectra DA score could be used to predict the optimal choice of second-line treatment for 157 patients with RA who were incomplete responders to the immunosuppressant methotrexate (MTX). More...
The findings demonstrated that, in patients with early RA and incomplete response to MTX, the Vectra DA test predicted the relative efficacy of second-line treatment with triple therapy versus anti-TNF. A Vectra DA score above 44 being indicative of high disease activity.

Vectra DA is manufactured by Crescendo Bioscience (South San Francisco, CA, USA). Two other studies presented provide guidance to physicians about discontinuation of therapy. One found that patients with a high Vectra DA score and positive results on a single-biomarker test had relapse rate of 76%, compared to 32% among those with a low Vectra DA score. A third study found that high Vectra DA scores were correlated with relapse of the disease in patients tapering their drug therapies. Vectra DA can help identify patients who show clinical improvement, but continue to have high levels of underlying disease activity, making them vulnerable to relapses or flares.

Elena Hitraya, MD, PhD, Chief Medical Officer at Crescendo, said, “The immunosuppressant methotrexate is the first-line therapy for rheumatoid arthritis, but it isn't always effective. At this point physicians need to make a choice. The options that they have is adding a synthetic biological drug, or adding a biological drug, which is most often anti-tumor necrosis factor (TNF).” The studies were presented at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) meeting being held November 7–11, 2015, in San Francisco (CA, USA).

Related Links:

Helsingborg Hospital 
Crescendo Bioscience 



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Gold Member
Thyroid-Stimulating Hormone Test
ULTRA-TSH
New
Calprotectin Test
CALiaGold
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: A biomarker discovery pipeline has shown promise as a noninvasive method of diagnosing CRC (Photo courtesy of NCI Center for Cancer Research)

Machine Learning Tool Enables Noninvasive Diagnosis and Monitoring of Colorectal Cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States when considering both genders. Colonoscopy remains the gold standard for CRC diagnosis, but it is invasive,... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.